Mp25-20 Salvage Focal Therapy for Radio-Recurrent Prostate Cancer: Oncologic Control and Functional Outcomes

You have accessJournal of UrologyProstate Cancer: Localized: Ablative Therapy I (MP25)1 May 2024MP25-20 SALVAGE FOCAL THERAPY FOR RADIO-RECURRENT PROSTATE CANCER: ONCOLOGIC CONTROL AND FUNCTIONAL OUTCOMES Masatomo Kaneko, Lorenzo Storino Ramacciotti, Divyangi Paralkar, Giovanni E. Cacciamani, Michelle Hopstone, Manju Aron, Osamu Ukimura, Inderbir S. Gill, and Andre Luis Abreu Masatomo KanekoMasatomo Kaneko , Lorenzo Storino RamacciottiLorenzo Storino Ramacciotti , Divyangi ParalkarDivyangi Paralkar , Giovanni E. CacciamaniGiovanni E. Cacciamani , Michelle HopstoneMichelle Hopstone , Manju AronManju Aron , Osamu UkimuraOsamu Ukimura , Inderbir S. GillInderbir S. Gill , and Andre Luis AbreuAndre Luis Abreu View All Author Informationhttps://doi.org/10.1097/01.JU.0001008692.26556.39.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To assess oncologic, functional outcomes and complications of salvage partial gland Cryoablation (sCRYO) and High Intensity Focused Ultrasound (sHIFU) for radio-recurrent prostate cancer (PCa). METHODS: Patients who underwent sCRYO or sHIFU with curative intent for localized radio-recurrent PCa were identified (IRB# HS-17-00749). Patients were monitored by prostate biopsy (PBx) 6-12mo and every 2yr thereafter. The primary endpoint was treatment failure (TF) defined as any radical treatment, systemic therapy, metastases, or PCa-specific mortality. Secondary endpoints were survival-free from i) biochemical failure (BF, PSA nadir + 2ng/mL); ii) Grade Group (GG) ≥2 on follow up PBx, and iii) radical treatment. Survival was assessed by Kaplan-Meier. Functional outcomes were assessed by International Prostate Symptom Score (IPSS), and International Index of Erectile Function (IIEF-5). 90-day postoperative Clavien-Dindo complications are recorded. Statistically significant if p3) was observed in both groups. The median difference from pre- to post-treatment IPSS (0 vs 0; p=1.0) and IIEF-5 score (0 vs 6; p=0.052) were similar for sCRYO vs sHIFU, respectively. Continence (defined as zero pad) was maintained at 91% for CRYO and 100% for HIFU (p=1.0). CONCLUSIONS: Salvage hemi gland CRYO and HIFU for radio-recurrent PCa provide comparable and acceptable short to medium-term oncologic outcomes, with low complications and preserved urogenital functions. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e412 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Masatomo Kaneko More articles by this author Lorenzo Storino Ramacciotti More articles by this author Divyangi Paralkar More articles by this author Giovanni E. Cacciamani More articles by this author Michelle Hopstone More articles by this author Manju Aron More articles by this author Osamu Ukimura More articles by this author Inderbir S. Gill More articles by this author Andre Luis Abreu More articles by this author Expand All Advertisement PDF downloadLoading ...